We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+15.55%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.22B
AUM Growth
+$106M
Cap. Flow
+$6.46M
Cap. Flow %
0.53%
Top 10 Hldgs %
47.36%
Holding
68
New
14
Increased
14
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$40.8M
2
ABBV icon
AbbVie
ABBV
+$33.3M
3
HCA icon
HCA Healthcare
HCA
+$31.2M
4
CI icon
Cigna
CI
+$27.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.7M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$50.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$41.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$21.6M
4
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$21.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 85.69%
2 Financials 2.76%
3 Communication Services 1.41%
4 Technology 1.32%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$98.2M 8.05%
13,623,620
+498,026
+4% +$3.68M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$89.1M 7.3%
6,297,523
+465,295
+8% +$5.59M
BHC icon
3
Bausch Health
BHC
$1.7B
$85.4M 7%
384,506
+115,987
+43% +$25.7M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$66.7M 5.47%
759,479
-141,400
-16% -$12.1M
TEVA icon
5
Teva Pharmaceuticals
TEVA
$36.5B
$57.2M 4.69%
967,359
+113,386
+13% +$6.99M
AGN
6
DELISTED
Allergan plc
AGN
$41.5M 3.4%
+136,818
New +$40.8M
KYTH
7
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$36.3M 2.98%
482,556
+257,494
+114% +$13.8M
HCA icon
8
HCA Healthcare
HCA
$82.1B
$35.4M 2.9%
+390,000
New +$31.2M
ABBV icon
9
AbbVie
ABBV
$451B
$34.3M 2.81%
+510,010
New +$33.3M
AET
10
DELISTED
Aetna Inc
AET
$33.7M 2.76%
264,075
+52,101
+25% +$5.95M
CMRX
11
DELISTED
Chimerix, Inc.
CMRX
$32.3M 2.65%
699,425
-145,031
-17% -$5.81M
CI icon
12
Cigna
CI
$75.7B
$32.2M 2.64%
+198,700
New +$27.4M
BIIB icon
13
Biogen
BIIB
$29.7B
$32M 2.62%
79,118
-18,595
-19% -$7.46M
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.5B
$28.4M 2.33%
+207,744
New +$25.7M
RCPT
15
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$27.4M 2.25%
144,205
-15,208
-10% -$2.51M
JAZZ icon
16
Jazz Pharmaceuticals
JAZZ
$15.6B
$26.6M 2.18%
150,866
+50,866
+51% +$9.14M
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$25.6M 2.1%
529,199
-523,467
-50% -$21.6M
UHS icon
18
Universal Health Services
UHS
$9.05B
$25M 2.05%
+175,965
New +$22M
HNT
19
DELISTED
HEALTH NET INC
HNT
$24.9M 2.04%
388,128
+117,770
+44% +$7.04M
ALR
20
DELISTED
Alere Inc
ALR
$24.3M 1.99%
461,170
-202,968
-31% -$10.2M
NSTG
21
DELISTED
NanoString Technologies, Inc.
NSTG
$22.5M 1.84%
1,459,742
+382,100
+35% +$5.11M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$21.2M 1.74%
+290,350
New +$18.7M
INSM icon
23
Insmed
INSM
$23.2B
$21.2M 1.74%
867,346
-514,482
-37% -$11.7M
ATRA icon
24
Atara Biotherapeutics
ATRA
$75M
$19.7M 1.61%
14,906
+4,298
+41% +$4.93M
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$19.5M 1.6%
610,171
-58,500
-9% -$1.48M
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q2 2015 Portfolio in Review

As of Q2 2015, Redmile Group held 68 positions worth $1.22B, up 9.6% from $1.11B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group's Q2 2015 filing shows 14 new, 14 increased, 24 reduced and 13 closed positions. Its largest new stake was Allergan plc: 136,818 shares worth $41.5M. The largest sale was Endo International plc, an estimated $50.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2015 buy was Allergan plc: 136,818 shares worth $41.5M.
  • Redmile Group added most to Bausch Health in Q2 2015, an estimated $25.7M increase.
  • Redmile Group's biggest Q2 2015 reduction was Seagen Inc. Common Stock, cutting an estimated $21.6M.
  • Redmile Group fully exited Endo International plc in Q2 2015, selling an estimated $50.3M.
  • Redmile Group's ten largest holdings make up 47% of its $1.22B portfolio in Q2 2015.
  • Redmile Group opened 14 new positions and closed 13 in Q2 2015.
  • Redmile Group's portfolio value rose 9.6% quarter-over-quarter to $1.22B.

Based on Redmile Group's 13F filing for Q2 2015, filed 14 Aug 2015.